Geneva, June 22 -- International Clinical Trials Registry received information related to the study (NCT07645833) titled 'Eptinezumab for Chronic Headache in Idiopathic Intracranial Hypertension' on June 9.

Study Type: Interventional

Study Design: Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Triple (Participant, Care Provider, Outcomes Assessor).

Primary Sponsor: Rigmor Højland Jensen

Condition: Idiopathic Intracranial Hypertension (IIH)

Intervention: Drug: Eptinezumab

Recruitment Status: Not recruiting

Phase: Phase 3

Date of First Enrollment: June 22, 2026

Target Sample Size: 96

To know more, visit https://clinicaltrials.gov/study/NCT07645833

Published by HT ...